<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9436057</journal-id>
<journal-id journal-id-type="pubmed-jr-id">8553</journal-id>
<journal-id journal-id-type="nlm-ta">Ophthalmic Genet</journal-id>
<journal-id journal-id-type="iso-abbrev">Ophthalmic Genet.</journal-id>
<journal-title-group>
<journal-title>Ophthalmic genetics</journal-title>
</journal-title-group>
<issn pub-type="ppub">1381-6810</issn>
<issn pub-type="epub">1744-5094</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28112973</article-id>
<article-id pub-id-type="pmc">5557692</article-id>
<article-id pub-id-type="doi">10.1080/13816810.2016.1257029</article-id>
<article-id pub-id-type="manuscript">NIHMS888598</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Spectral-domain optical coherence tomography findings in Alström syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Dotan</surname>
<given-names>Gad</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khetan</surname>
<given-names>Vikas</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Marshall</surname>
<given-names>Jan D.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Affel</surname>
<given-names>Elizabeth</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Armiger-George</surname>
<given-names>Denise</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Naggert</surname>
<given-names>Jürgen K</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Collin</surname>
<given-names>Gayle B</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Levin</surname>
<given-names>Alex V.</given-names>
</name>
<degrees>MD, MHSc</degrees>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Ophthalmology Department, Tel Aviv Medical Center, Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel</aff>
<aff id="A2">
<label>2</label>Pediatric Ophthalmology and Ocular Genetics, Wills Eye Hospital, Philadelphia, PA</aff>
<aff id="A3">
<label>3</label>The Jackson Laboratory, Bar Harbor, ME</aff>
<aff id="A4">
<label>4</label>Bioptigen Inc., Research Triangle Park, NC</aff>
<author-notes>
<corresp id="FN1"><bold>Contact information:</bold> Alex V. Levin, Wills Eye Hospital, Ste. 1210, 840 Walnut Street, Philadelphia, PA 19107-5109 (<email>alevin@willseye.org</email>), Tel: 215-928-3000</corresp>
<fn fn-type="COI-statement" id="FN2">
<p id="P28"><bold>Declaration of Interest</bold>: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>29</day>
<month>6</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>23</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<season>Sep-Oct</season>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>9</month>
<year>2018</year>
</pub-date>
<volume>38</volume>
<issue>5</issue>
<fpage>440</fpage>
<lpage>445</lpage>
<!--elocation-id from pubmed: 10.1080/13816810.2016.1257029-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">Alström syndrome is a multi-system recessive disorder caused by mutations in <italic>ALMS1</italic> gene. The aim of this study was to characterize morphological retinal changes in Alström patients using spectral-domain optical coherence tomography.</p>
</sec>
<sec id="S2">
<title>Methods</title>
<p id="P2">We studied volunteer patients attending the conference of Alström Syndrome International, a support group for affected families, using hand-held spectral-domain optical coherence tomography (SD-OCT) in an office setting. Patients had a clinical dilated retinal examination. Past medical records were reviewed.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">Twenty-two Alström patients (mean age 17 years, range 2 – 38 years, 12 males) were studied. OCT imaging demonstrated that central macular OCT changes are often mild during the first decade of life and gradually progress, demonstrating disruption of normal retinal architecture, and progressive loss of photoreceptors and retinal pigment epithelium with increased prominence of choroidal vasculature. Other changes found included hyperreflectivities in all retinal layers, severe retinal wrinkling, optic nerve drusen and vitreoretinal separation. Vision correlated with severity of OCT macular changes (r=0.89, P=0.002).</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P4">This study reports on OCT findings in a large group of patients with Alström syndrome. We document a panretinal gradual progression of retinal changes, which are often mild during the first years of life. Previously unreported observations include intraretinal opacities, optic nerve drusen and foveal contour abnormalities. Morphological retinal changes demonstrated by SD-OCT may help in understanding the pathophysiology of the disease and defining strategies for treatment such as gene therapy.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Optical coherence tomography</kwd>
<kwd>Alström syndrome</kwd>
<kwd>ocular genetics</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>